NextCure, Inc. Common Stock
NXTCStock
$6.17+39.29%52W
Market Cap$21.82M
P/E—
Div yield—
Beta1.46
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-62.03%
Price vs S&P 500 (4W)237.67%
VGM Score67.63
Market Capitalization$21.82M
Earnings Surprise History
Q1 26-1.87est. -2.15
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.22
4.22
4.22
4.22
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NXTCNextCure, Inc. Common Stock | A | — | C | $6.17 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
NextCure is a clinical-stage biopharmaceutical company developing immunomedicines to restore immune function in cancer and immune-related diseases. Its lead candidate, NC410, a LAIR-2 fusion protein, demonstrated early clinical activity in colorectal and ovarian cancers in combination with pembrolizumab, while LNCB74, an antibody-drug conjugate targeting B7-H4, is also in clinical development. The company is seeking strategic partners for additional clinical programs including NC525 and NC318, as well as preclinical candidates in chronic bone diseases and neurological indications.